Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fusion Pharmaceuticals Inc FUSN

Healthcare Biotechnology
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by... see more

Recent & Breaking News (NDAQ:FUSN)

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire May 4, 2022

Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 26, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 30, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 24, 2022

Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates

PR Newswire March 17, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 9, 2022

Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference

PR Newswire February 28, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire February 9, 2022

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

PR Newswire January 21, 2022

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire January 18, 2022

Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals

PR Newswire January 11, 2022

Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals

PR Newswire January 11, 2022

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

PR Newswire January 10, 2022

Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference

PR Newswire November 11, 2021

Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update

PR Newswire November 9, 2021

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 3, 2021

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

PR Newswire November 2, 2021

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

PR Newswire October 20, 2021

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

PR Newswire September 28, 2021

Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

PR Newswire September 23, 2021